secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0000950170-25-077374
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome settles SUNOSI patent litigation with Hetero; generic entry delayed until 2040
--------------------------------------------------------------------------------

- Settlement resolves patent litigation with Hetero over generic version of SUNOSI (solriamfetol).
- Hetero licensed to sell generic SUNOSI on or after Sept 1, 2040 (if pediatric exclusivity) or March 1, 2040.
- Settlement agreement subject to review by FTC and DOJ.
- Similar patent litigation against other SUNOSI generic applicants remains pending in New Jersey court.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/0000950170-25-077374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025077374/axsm-20250527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-077374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer